Femoral Artery StenosisSFA ISRNCT02063672
Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
A study testing Lutonix DCB and Standard Uncoated Balloon Angioplasty Catheter in people with Femoral Artery Stenosis and Femoral Artery Occlusion, run by C. R. Bard at 20 sites in United States.
Trial summary
To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of femoropopliteal artery (SFA) in-stent restenosis (ISR). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Femoral Artery Stenosis, Femoral Artery Occlusion, Restenosis
- What is being tested?
- Lutonix DCB and Standard Uncoated Balloon Angioplasty Catheter
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 82 participants
- Where
- 20 sitesUnited States
- Study dates
- Mar 2014to Mar 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or non-pregnant female ≥18 years of age
- Rutherford Clinical Category 2-4
- Significant (≥ 50%) restenosis of a previous bare (not covered and not drug-eluting) nitinol stent(s) in the femoropopliteal artery
- Lesion measures between 4 and 18 cm
- Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix
- A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography
Show all 9Show fewer
- Successful crossing and predilatation of the target lesion with a guidewire
- At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography that has not previously been (nor planned to be) revascularized
- No other prior vascular or surgical interventions within 2 weeks before and/or planned 30 days after the protocol treatment
Who cannot join
- Life expectancy of <1 year
- Patient is currently participating in an investigational drug or other device study or previously enrolled in this study NOTE: Enrollment in another drug or device clinical trial during the follow up period is not allowed
- History of stroke within 3 months
- History of MI, thrombolysis or angina within 2 weeks of enrollment
- Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion
- Target lesion involves a previously placed covered stent or drug-eluting stent
Show all 10Show fewer
- Grade 4 or 5 stent fracture (mal-aligned components or trans-axial spiral configuration) in the restenotic stent
- Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication
- Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion
- Intended use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, stents, etc.)
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
United States20 sites
TriHealth, Inc.
Cincinnati, Ohio, 45220
Northwestern University
Evanston, Illinois, 60208
Cardiology Associates
Fairhope, Alabama, 36532
Hunterdon Cardiovascular Associates
Flemington, New Jersey, 08822
University of Texas Medical Branch
Galveston, Texas, 77555
Hattiesburg Clinic, PA
Hattiesburg, Mississippi, 39401
Jackson Heart Clinic, P.A.
Jackson, Mississippi, 39216
Wellmont Cardiology Services, Inc.
Kingsport, Tennessee, 37660
Radiology and Imaging Specialists of Lakeland, P.A.
Lakeland, Florida, 33805
Mount Sinai Medical Center
Miami, Florida, 33140
Aurora Medical Group
Milwaukee, Wisconsin, 53215
Yale University
New Haven, Connecticut, 06510
Kansas City Vascular Foundation
North Kansas City, Missouri, 64116
Minneapolis Radiology and Vascular Research Foundation
Plymouth, Minnesota, 55441
The Miriam Hospital - A Lifespan Partner
Providence, Rhode Island, 02906
Rex Hospital, Inc.
Raleigh, North Carolina, 27607
Virginia Commonwealth University
Richmond, Virginia, 23219
William Beaumont Hospital Research Institute
Royal Oak, Michigan, 48073
MedStar Health Research Institute
Washington D.C., District of Columbia, 20010
Metropolitan Hospital d/b/a Metro Health Hospital
Wyoming, Michigan, 49519
About this study
Official title: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of femoropopliteal artery (SFA) in-stent restenosis (ISR).
- Being tested
- Lutonix DCB, Standard Uncoated Balloon Angioplasty Catheter
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lutonix DCBDevice
Standard Uncoated Balloon Angioplasty CatheterDevice
PTA Catheter
| Study group | Role | What they receive |
|---|---|---|
| Lutonix DCB | Experimental | Lutonix Paclitaxel Drug Coated Balloon Receives: Device: Lutonix DCB |
| PTA Catheter | Active comparator | Standard Uncoated Balloon Angioplasty Catheter Receives: Device: Standard Uncoated Balloon Angioplasty Catheter |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Primary Patency at 1 Year
Primary patency is defined as freedom from clinically driven target lesion restenosis (TLR) and from Binary Restenosis.
Measured: 12 Months
Percentage of Participants Without Primary Safety Events
Primary Safety Events include: All Cause Perioperative (≤30 day) Death, Index Limb Amputation, Index Limb Reintervention and Index Limb Related Death at 1 Year
Measured: 12 Months
Secondary outcomes (18)
Percentage of Participants With Device Success
Device success is defined as, on a per device basis, the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.
Measured: During the Index Procedure (90 mins)
Percentage of Participants With Technical Success
Technical success of the balloon procedure is defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion and a successful withdrawal of the study system with the achievement of < 30% residual percent stenosis without deployment of a bail-out stent.
Measured: During the Index Procedure (90 mins)
Percentage of Participants With Procedural Success
Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without major adverse events (defined as occurrence of death, amputation of the target limb, or repeat revascularization of the target lesion) during the index procedure and through the hospital stay.
Measured: During the Index Procedure (90 mins)
Percentage of Participants With Primary Patency at 6 and 12 Months
Primary Patency is defined as Freedom from CEC-adjudicated Clinically-Driven TLR and from Core laboratory-adjudicated Binary Restenosis. Binary restenosis is based on threshold Doppler peak systolic velocity ratio (PSVR) ≥ 2.5 (together with waveform analysis \& color mosaic appearance) or based on angiographic ≥ 50% diameter stenosis (if angiography is performed although not required per protocol).
Measured: 6 months and 12 months
Percentage of Participants With Secondary Patency at 6 Months and 12 Months
Secondary patency is defined as the absence of Binary Restenosis as adjudicated by the blinded, independent core laboratory, independent of whether or not patency is re-established via an endovascular procedure.
Measured: 6 months and 12 months
Percentage of Participants Without Clinically Driven Target Lesion Revascularization (TLR)
Clinically-driven TLR is defined as revascularization of the target vessel with evidence of target vessel diameter stenosis >50% determined by duplex ultrasound or angiography and new distal ischemic signs (worsening ABI or worsening Rutherford Category associated with the target limb or due to clinical symptoms), OR revascularization of a target vessel with an in-lesion diameter stenosis of >70% by angiography, in the absence of the previously mentioned ischemic signs or symptoms.
Measured: 6 months and 12 months
Percentage of Participants Without Target Lesion Revascularization (TLR)
TLR is defined as any repeat revascularization procedure (percutaneous or surgical) of the original target lesion site.
Measured: 6 months and 12 months
Percentage of Participants With Sustained Clinical Benefit Compared to Baseline
Sustained clinical benefit is defined as an improvement in Rutherford Classification compared to baseline and freedom from target vessel revascularization. The Rutherford classification is a clinical means of describing peripheral artery disease along a seven-stage scale, with stage 0 representing asymptomatic presentation and stage 6 representing severe ischemic ulcers or frank gangrene. A decrease in units on the scale represents improvement in clinical symptoms.
Measured: 6 months and 12 months
Change of Rutherford Classification From Baseline
The Rutherford classification is a clinical means of describing peripheral artery disease along a seven-stage scale, with stage 0 representing asymptomatic presentation and stage 6 representing severe ischemic ulcers or frank gangrene. A decrease in units on the scale represents improvement in clinical symptoms.
Measured: 6 months and 12 months
Change of Resting Ankle Brachial Index (ABI) From Baseline
The ankle-brachial index (ABI) is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm (brachium).
Measured: 6 months and 12 months
Change in Walking Impairment Questionnaire From Baseline
The Walking Impairment Questionnaire (WIQ) is a validated questionnaire that evaluates walking ability with a focus on walking distance, walking speed, and the ability to climb stairs. Participants answer each item on a Likert scale from 0 for "unable to do" to 4 for "no difficulty", and each response is weighted based on the difficulty of the task. The overall score is determined by dividing the weighted answers by the maximum possible weighted score and multiplying by 100. The overall score ranges from 0-100 with lower scores indicating lower performance.
Measured: 6 months and 12 months
Change in Quality of Life From Baseline
EQ-5D is a standardized tool to assess patient-reported mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, or slight, moderate, severe, or extreme problems. Patients choose the appropriate level in each of the 5 dimensions, which results in a 1-digit number for each dimension. The digits for the 5 dimensions are converted into a single EQ-5D™ index score based on a set of population-based preference weights. For the U.S. general population, possible EQ-5D™ index scores range from -0.11 (i.e., 33333) to 1.0 (i.e., 11111) on a scale where 0.0 = death and 1.0 = perfect health. A downloadable scoring file is available at: https://www.ahrq.gov/rice/EQ5Dscore.htm.
The EQ VAS records a patient's self-rated health on a vertical visual analogue scale, where the endpoints are labeled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). A higher VAS value indicates a higher quality of life.
Measured: 6 months and 12 Months
Percentage of Participants Without Major Vascular Complications (≤30 Day)
Freedom from major vascular complications at 30 days follow-up
Measured: 30 Days
Percentage of Participants Without All-Cause Death
Mortality from any cause.
Measured: 1 month, 6 months, and 12 months
Percentage of Participants Without Major Limb Amputation
Major limb amputation is defined as amputation of the lower limb above the ankle.
Measured: 1 month, 6 months, and 12 months
Percentage of Participants Without Minor Limb Amputation
Minor limb amputation is defined as amputation of a part of the foot below the ankle.
Measured: 1 month, 6 months, and 12 months
Percentage of Participants Without Target Vessel Revascularizations (TVR)
A TVR is defined as a repeat revascularization procedure (percutaneous or surgical) of a lesion in the target vessel.
Measured: 1 month, 6 months, and 12 months
Percentage of Participants Without Any Target Limb Reinterventions
Any surgical intervention in the target limb.
Measured: 1 month, 6 months, and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Feb 2014 (estimated)
- Study startMar 2014
- Primary completion13 Feb 2017
- Study completionMar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Femoral Artery StenosisStudies of the same condition, open and under way.
- More trials run by C. R. BardThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- C. R. Bard
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Carlos Mena, MD, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02063672
- Sponsor's protocol ID
- CL0018-01
- Acronym
- SFA ISR
- Status last verified
- Mar 2019
- First submitted
- 12 Feb 2014
- Last updated
- 11 Apr 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
- ClinicalTrials.gov ID
- NCT02063672
- Acronym / sponsor ID
- SFA ISR / CL0018-01
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- C. R. BardIndustry (pharma, biotech, devices)
- Study start
- Mar 2014
- Primary completion
- 13 Feb 2017 (actual)
- Study completion
- Mar 2019 (actual)
- First posted
- 14 Feb 2014 (estimated)
- Results
- Posted 23 May 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of femoropopliteal artery (SFA) in-stent restenosis (ISR).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lutonix DCB | Experimental | Device: Lutonix DCBLutonix Paclitaxel Drug Coated Balloon |
| PTA Catheter | Active comparator | Device: Standard Uncoated Balloon Angioplasty CatheterStandard Uncoated Balloon Angioplasty Catheter |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Male or non-pregnant female ≥18 years of age
- Rutherford Clinical Category 2-4
- Significant (≥ 50%) restenosis of a previous bare (not covered and not drug-eluting) nitinol stent(s) in the femoropopliteal artery
- Lesion measures between 4 and 18 cm
- Target vessel diameter between ≥4 and ≤6 mm and able to be treated with available device size matrix
Key exclusion criteria (10 listed)
- Life expectancy of <1 year
- Patient is currently participating in an investigational drug or other device study or previously enrolled in this study NOTE: Enrollment in another drug or device clinical trial during the follow up period is not allowed
- History of stroke within 3 months
- History of MI, thrombolysis or angina within 2 weeks of enrollment
- Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lutonix DCB | Device | Lutonix DCB |
| Standard Uncoated Balloon Angioplasty CatheterPTA Catheter | Device | PTA Catheter |
Primary outcome
Percentage of Participants With Primary Patency at 1 Year
Time frame: 12 Months
Primary patency is defined as freedom from clinically driven target lesion restenosis (TLR) and from Binary Restenosis.
Percentage of Participants Without Primary Safety Events
Time frame: 12 Months
Primary Safety Events include: All Cause Perioperative (≤30 day) Death, Index Limb Amputation, Index Limb Reintervention and Index Limb Related Death at 1 Year
18 secondary outcomes
Percentage of Participants With Device Success
Time frame: During the Index Procedure (90 mins)
Percentage of Participants With Technical Success
Time frame: During the Index Procedure (90 mins)
Percentage of Participants With Procedural Success
Time frame: During the Index Procedure (90 mins)
Percentage of Participants With Primary Patency at 6 and 12 Months
Time frame: 6 months and 12 months
Percentage of Participants With Secondary Patency at 6 Months and 12 Months
Time frame: 6 months and 12 months
Percentage of Participants Without Clinically Driven Target Lesion Revascularization (TLR)
Time frame: 6 months and 12 months
Percentage of Participants Without Target Lesion Revascularization (TLR)
Time frame: 6 months and 12 months
Percentage of Participants With Sustained Clinical Benefit Compared to Baseline
Time frame: 6 months and 12 months
Change of Rutherford Classification From Baseline
Time frame: 6 months and 12 months
Change of Resting Ankle Brachial Index (ABI) From Baseline
Time frame: 6 months and 12 months
Change in Walking Impairment Questionnaire From Baseline
Time frame: 6 months and 12 months
Change in Quality of Life From Baseline
Time frame: 6 months and 12 Months
Percentage of Participants Without Major Vascular Complications (≤30 Day)
Time frame: 30 Days
Percentage of Participants Without All-Cause Death
Time frame: 1 month, 6 months, and 12 months
Percentage of Participants Without Major Limb Amputation
Time frame: 1 month, 6 months, and 12 months
Percentage of Participants Without Minor Limb Amputation
Time frame: 1 month, 6 months, and 12 months
Percentage of Participants Without Target Vessel Revascularizations (TVR)
Time frame: 1 month, 6 months, and 12 months
Percentage of Participants Without Any Target Limb Reinterventions
Time frame: 1 month, 6 months, and 12 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Apr 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Femoral Artery Stenosis
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Active, not recruiting
SELUTION4SFA Trial
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
Active, not recruiting
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
Recruiting
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
Aortic Stenosis
Not yet recruitingPhase 2/3
A Study Comparing the MAGICTouch™ Sirolimus-coated Balloon With a Paclitaxel-coated Balloon for Treating Severe Narrowing or Blockage in the Femoropopliteal Arteries.
Popliteal Artery Disease, Superficial Femoral Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carlos Mena, MD principal investigator
Yale University
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lutonix DCB and Standard Uncoated Balloon Angioplasty Catheter in people with Femoral Artery Stenosis and Femoral Artery Occlusion, run by C. R. Bard at 20 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 May 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Primary Patency at 1 Year (time frame: 12 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2019.